Evidence map›Paper›PMID 40964235›Full record

ArticleAutophagy reports2025

Biarylacetamides: a novel class of late-stage autophagy inhibitors.

Mélissa Lallier, Rani Robeyns, Freke Mertens, Angela Sisto, Guido R Y De Meyer, Koen Augustyns, Maya Berg, Winnok H De Vos, Vincent Timmerman, George M C Janssen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Autophagy reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mélissa LallierLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-0254-3124
Rani RobeynsToxicological Centre, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-3695-3490
Freke MertensLaboratory of Physiopharmacology, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-6091-5291
Angela SistoPeripheral Neuropathy Research Group, Department of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium.ORCID https://orcid.org/0000-0002-7582-0623
Guido R Y De MeyerLaboratory of Physiopharmacology, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-3848-8702
Koen AugustynsLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-5203-4339
Maya BergInfla-Med Centre of Excellence, University of Antwerp, Antwerpen, Belgium.
Winnok H De VosAntwerp Centre for Advanced Microscopy, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-0960-6781
Vincent TimmermanPeripheral Neuropathy Research Group, Department of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium.ORCID https://orcid.org/0000-0002-2162-0933
George M C JanssenCenter for Proteomics and Metabolomics, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Peter van VeelenCenter for Proteomics and Metabolomics, Leiden University Medical Center (LUMC), Leiden, Netherlands.ORCID https://orcid.org/0000-0002-7898-9408
Alexander L N van NuijsToxicological Centre, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-9377-6160
Nikolai EngedalAutophagy in Cancer Lab, Department of Tumor Biology, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0003-3718-3464
Wim MartinetLaboratory of Physiopharmacology, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-1967-9343
Pieter Van der VekenLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-1208-3571

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting autophagy is believed to hold great promise for the treatment of various diseases, including cancer. However, since the therapeutic efficacy of currently available autophagy-modulating drugs is limited by off-target effects and the requirement of high dosage, there is an urgent need to develop novel autophagy-targeting compounds. In this study, we report molecules of the biarylacetamide class as novel autophagy inhibitors. These molecules were identified via phenotypic high-throughput screening, and a series of analogues was subsequently synthesized. Among these,

Indexed as

Autophagy inhibitorbiarylacetamide derivativescholesterol biosynthesisdrug discoverylipidomicsmedicinal chemistrymetabolomicsproteomics

Identifiers

PMID40964235
PMCPMC12439681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.